Immunoinflammatory diseases of the central nervous system - The tale of two cytokines

British Journal of Pharmacology

Volumn 173, Issue 4, 2016, Pages 716-728

  Hofer, M J ^a   Campbell, I L ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 6; ANTIINFLAMMATORY AGENT;

AICARDI GOUTIERES SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE PRODUCTION; DISEASE MODEL; GENETIC ASSOCIATION; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC TRANSVERSE MYELITIS; MOLECULAR PATHOLOGY; MYELITIS; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; METABOLISM; NERVOUS SYSTEM DISEASES; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM; HUMANS; INFLAMMATION; INTERFERON-ALPHA; INTERLEUKIN-6; NERVOUS SYSTEM DISEASES;

EID: 84957546102     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13175     Document Type: Review

References (152)

1. Aicardi J, (2002). Aicardi-Goutieres syndrome: special type early-onset encephalopathy. Eur J Paediatr Neurol 6 (Suppl. A): A1-A7.
2. Aicardi J, Goutieres F, (1984). A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 15: 49-54.
3. Akahoshi M, Nakashima H, Sadanaga A, Miyake K, Obara K, Tamari M, et al. (2008). Promoter polymorphisms in the IRF3 gene confer protection against systemic lupus erythematosus. Lupus 17: 568-574.
4. Akwa Y, Hassett DE, Eloranta ML, Sandberg K, Masliah E, Powell H, et al. (1998). Transgenic expression of IFN-a in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 161: 5016-5026.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
7. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
8. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T, (2013). Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 23: 827-831.
9. Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. (2014). Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82: 1302-1306.
10. Ayzenberg I, Kleiter I, Schroder A, Hellwig K, Chan A, Yamamura T, et al. (2013). Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70: 394-397.
11. Barnett MH, Sutton I, (2012). Neuromyelitis optica: not a multiple sclerosis variant. Curr Opin Neurol 25: 215-220.
12. Barnum SR, Jones JL, Muller-Ladner U, Samimi A, Campbell IL, (1996). Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted interleukin-6 expression. Glia 18: 107-117.
13. Bellinger FP, Madamba SG, Campbell IL, Siggins G, (1995). Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci Letts 198: 95-98.
14. Belman AL, Lantos G, Horoupian D, Novick BE, Ultmann MH, Dickson DW, et al. (1986). Calcification of the basal ganglia in infants and children with acquired immunodeficiency syndrome. Neurology 36: 1192-1199.
15. Black DN, Booth F, Watters GV, Andermann E, Dumont C, Halliday WC, et al. (1988a). Leukoencephalopathy among native Indian infants in northern Quebec and Manitoba. Ann Neurol 24: 490-496.
16. Black DN, Watters GV, Andermann E, Dumont C, Kabay ME, Kaplan P, et al. (1988b). Encephalitis among Cree children in Northern Quebec. Ann Neurol 24: 483-489.
17. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J, (2001). Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294: 1540-1543.
18. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, et al. (2012). Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 337: 1684-1688.
19. van Boxel-Dezaire AH, Rani MR, Stark GR, (2006). Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25: 361-372.
20. Brett FM, Mizisin AP, Powell HC, Campbell IL, (1995). Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 54: 766-775.
21. Brouwers P, Wolters P, Civitello L, (1998). Central nervous system manifestations and assessment. In:, Pizzo P, Wilfert CM, (eds). Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents, 3rd edn. Williams & Wilkins: Baltimore, pp. 293-308.
22. Burton MD, Sparkman NL, Johnson RW, (2011). Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior. J Neuroinflammation 8: 54.
23. Burton MD, Rytych JL, Freund GG, Johnson RW, (2013). Central inhibition of interleukin-6 trans-signaling during peripheral infection reduced neuroinflammation and sickness in aged mice. Brain Behav Immun 30: 66-72.
24. Calabrese LH, Rose-John S, (2014). IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 10: 720-727.
25. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, et al. (1993). Neurologic disease induced in transgenic mice by the cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 90: 10061-10065.
26. Campbell IL, Krucker T, Steffensen S, Akwa Y, Powell HC, Lane T, et al. (1999). Structural and functional neuropathology in transgenic mice with CNS expression of IFN-a. Brain Res 835: 46-61.
27. Campbell IL, Hofer MJ, Pagenstecher A, (2010). Transgenic models for cytokine-induced neurological disease. Biochim Biophys Acta 1802: 903-917.
28. Campbell IL, Erta M, Lim SL, Frausto R, May U, Rose-John S, et al. (2014). Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 34: 2503-2513.
29. Carrasco J, Hernandez J, Campbell IL, Hidalgo J, (1998). Localization of metallothionein-I and-III expression in the CNS of transgenic mice with astrocyte-targeted expression of interleukin-6. Exp Neurol 153: 184-194.
30. Chahwan C, Chahwan R, (2012). Aicardi-Goutieres syndrome: from patients to genes and beyond. Clin Genet 81: 413-420.
31. Chiang C-S, Stalder A, Samimi A, Campbell IL, (1994). Reactive gliosis as a consequence of interleukin-6 expression in the brain. Studies in transgenic mice. Dev Neurosci 16: 212-221.
32. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. (2011). Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706.
33. Civitello L, (2005). Neurologic problems. In:, Zeichner S, Read J, (eds). Textbook of Pediatric HIV Care. Cambridge University Press: New York, pp. 431-444.
34. Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A, (2011). The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. Cell Mol Immunol 8: 135-145.
35. Cook JE, Dasgupta S, Middaugh LD, Terry EC, Gorry PR, Wesselingh SL, et al. (2005). Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol 57: 795-803.
36. Crow YJ, (2011). Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 1238: 91-98.
37. Crow YJ, Livingston JH, (2008). Aicardi-Goutieres syndrome: an important Mendelian mimic of congenital infection. Dev Med Child Neurol 50: 410-416.
38. Crow YJ, Jackson AP, Roberts E, van Beusekom E, Barth P, Corry P, et al. (2000). Aicardi-Goutieres syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21. Am J Hum Genet 67: 213-221.
39. Crow YJ, Black DN, Ali M, Bond J, Jackson AP, Lefson M, et al. (2003). Cree encephalitis is allelic with Aicardi-Goutieres syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J Med Genet 40: 183-187.
40. Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, et al. (2006a). Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 38: 917-920.
41. Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, Griffith E, et al. (2006b). Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet 38: 910-916.
42. De Laet C, Goyens P, Christophe C, Ferster A, Mascart F, Dan B, (2005). Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutieres syndrome. Neuropediatrics 36: 399-402.
43. Deng Y, Tsao BP, (2010). Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 6: 683-692.
44. Dussaix E, Lebon P, Ponsot G, Huault G, Tardieu M, (1985). Intrathecal synthesis of different alpha-interferons in patients with various neurological diseases. Acta Neurol Scand 7: 504-509.
45. Eder PS, Walder JA, (1991). Ribonuclease H from K562 human erythroleukemia cells. Purification, characterization, and substrate specificity. J Biol Chem 266: 6472-6479.
46. Efthimiou P, Blanco M, (2009). Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 19: 457-468.
47. Ernst M, Jenkins BJ, (2004). Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 20: 23-32.
48. Erta M, Quintana A, Hidalgo J, (2012). Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 8: 1254-1266.
49. Fu Q, Zhao J, Qian X, Wong JL, Kaufman KM, Yu CY, et al. (2011). Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum 63: 749-754.
50. Funabiki M, Kato H, Miyachi Y, Toki H, Motegi H, Inoue M, et al. (2014). Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity 40: 199-212.
51. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, et al. (2011). HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480: 379-382.
52. Gonzalez-Navajas JM, Lee J, David M, Raz E, (2012). Immunomodulatory functions of type I interferons. Nat Rev Immunol 12: 125-135.
53. Gray F, Scaravilli F, Everall I, Chretien F, An S, Boche D, et al. (1996). Neuropathology of early HIV-1 infection. Brain Pathol 6: 1-15.
54. Hartner JC, Schmittwolf C, Kispert A, Muller AM, Higuchi M, Seeburg PH, (2004). Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem 279: 4894-4902.
55. Hartner JC, Walkley CR, Lu J, Orkin SH, (2009). ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol 10: 109-115.
56. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW, (2008). Astrocytes produce interferon-alpha and CXCL10, but not IL-6 or CXCL8, in Aicardi-Goutieres syndrome. Glia 56: 568-578.
57. Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH, (1997). Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA 94: 1500-1505.
58. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, et al. (1985). Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A 82: 5490-5494.
59. Hirano T, Yasukawa K, Harada H, Tage T, Watanabe Y, Matsuda T, et al. (1986). Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73-76.
60. Hirano T, Akira S, Taga T, Kishimoto T, (1990). Biological and clinical aspects of interleukin 6. Immunol Today 11: 443-449.
61. Hofer MJ, Campbell IL, (2013). Type I interferon in neurological disease-the devil from within. Cytokine Growth Factor Rev 24: 257-267.
62. Isaacs A, Lindenmann J, (1957). Virus interference. 1. The interferon. Proc R Soc Lond B 147: 258-267.
63. Ishikawa A, Murayama T, Sakuma N, Takase A, Shishido T, Nagamatsu K, et al. (1982). Computed cranial tomography in congenital rubella syndrome. Arch Neurol 39: 420-421.
64. Izzotti A, Pulliero A, Orcesi S, Cartiglia C, Longobardi MG, Capra V, et al. (2009). Interferon-related transcriptome alterations in the cerebrospinal fluid cells of Aicardi-Goutieres patients. Brain Pathol 19: 650-660.
65. John GR, Lee SC, Brosnan CF, (2003). Cytokines: powerful regulators of glial cell activation. Neuroscientist 9: 10-22.
66. Jonsen A, Bengtsson AA, Nived O, Ryberg B, Truedsson L, Ronnblom L, et al. (2003). The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 12: 846-850.
67. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. (2001). Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268: 160-167.
68. Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, et al. (2005). IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115: 2731-2741.
69. Kauffman WM, Sivit CJ, Fitz CR, Rakusan A, Herzog K, Chandra RS, (1992). CT and MR evaluation of intracranial involvement in pediatric HIV infection: a clinical imaging correlation. Am J Neuroradiol 13: 949-957.
70. Kenneson A, Cannon MJ, (2007). Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17: 253-276.
71. Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al. (2013). Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 70: 390-393.
72. Kirou KA, Gkrouzman E, (2013). Anti-interferon alpha treatment in SLE. Clin Immunol 148: 303-312.
73. Kishimoto T, (2005). Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21.
74. Krivine A, Force G, Servan J, Cabee A-E, Rozenberg F, Dighiero L, et al. (1999). Measuring HIV-1 RNA and interferon-a in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS Dementia Complex. J Neurovirol 5: 500-506.
75. Lauenstein AS, Stettner M, Kieseier BC, Lensch E, (2014). Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Rep 2014. doi: 10.1136/bcr-2013-202939
76. Lauwerys BR, Ducreux J, Houssiau FA, (2014). Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford) 53: 1369-1376.
77. Lebon P, Badoual J, Ponsot G, Goutieres F, Hemeury-Cukier F, Aicardi J, (1988). Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy. J Neurol Sci 84: 201-208.
78. Lebon P, Meritet JF, Krivine A, Rozenberg F, (2002). Interferon and Aicardi-Goutieres syndrome. Eur J Paediatr Neurol 6 (Suppl. A): A47-A53.
79. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. (2004). A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112.
80. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR, (2005). IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477.
81. Lin HW, Levison SW, (2009). Context-dependent IL-6 potentiation of interferon-gamma-induced IL-12 secretion and CD40 expression in murine microglia. J Neurochem 111: 808-818.
82. Liner KJ 2nd, Ro MJ, Robertson KR, (2010). HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 7: 85-91.
83. Linhares UC, Schiavoni PB, Barros PO, Kasahara TM, Teixeira B, Ferreira TB, et al. (2013). The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 33: 179-189.
84. Mannion NM, Greenwood SM, Young R, Cox S, Brindle J, Read D, et al. (2014). The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep 9: 1482-1494.
85. Marz P, Herget T, Lang E, Otten U, Rose-John S, (1997). Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation. Eur J Neurosci 9: 2765-2773.
86. Marz P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U, (1999). Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 26: 191-200.
87. Milner R, Campbell IL, (2006). Increased expression of the beta4 and alpha5 integrin subunits in cerebral blood vessels of transgenic mice chronically producing the pro-inflammatory cytokines IL-6 or IFN-alpha in the central nervous system. Mol Cell Neurosci 33: 429-440.
88. Mitchell CD, (2006). HIV-1 encephalopathy among perinatally infected children: neuropathogenesis and response to highly active antiretroviral therapy. Ment Retard Dev Disabil Res Rev 12: 216-222.
89. Morita M, Stamp G, Robins P, Dulic A, Rosewell I, Hrivnak G, et al. (2004). Gene-targeted mice lacking the Trex1 (DNase III) 3′→5′ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 24: 6719-6727.
90. Nelson TE, Olde Engberink A, Hernandez R, Puro A, Huitron-Resendiz S, Hao C, et al. (2012). Altered synaptic transmission in the hippocampus of transgenic mice with enhanced central nervous systems expression of interleukin-6. Brain Behav Immun 26: 959-971.
91. Noorbehesht B, Enzmann DR, Sullender W, Bradley JS, Arvin AM, (1987). Neonatal herpes simplex encephalitis: correlation of clinical and CT findings. Radiology 162: 813-819.
92. Oda H, Nakagawa K, Abe J, Awaya T, Funabiki M, Hijikata A, et al. (2014). Aicardi-Goutieres syndrome is caused by IFIH1 mutations. Am J Hum Genet 95: 121-125.
93. Pascual V, Banchereau J, Palucka AK, (2003). The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 15: 548-556.
94. Paul S, Ricour C, Sommereyns C, Sorgeloos F, Michiels T, (2007). Type I interferon response in the central nervous system. Biochimie 89: 770-778.
95. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
96. Perrella O, Carreiri PB, Perrella A, Sbreglia C, Gorga F, Guarnaccia D, et al. (2001). Transforming growth factor beta-1 and interferon-alpha in the AIDS dementia complex (ADC): possible relationship with cerebral viral load? Eur Cytokine Netw 12: 51-55.
97. Petito CK, Adkins B, McCarthy M, Roberts B, Khamis I, (2003). CD4+ and CD8+ cells accumulate in the brains of acquired immunodeficiency syndrome patients with human immunodeficiency virus encephalitis. J Neurovirol 9: 36-44.
98. Pontrelli L, Pavlakis S, Krilov LR, (1999). Neurobehavioral manifestations and sequelae of HIV and other infections. Child Adolesc Psychiatr Clin N Am 8: 869-878.
99. Quintana A, Muller M, Frausto RF, Ramos R, Getts DR, Sanz E, et al. (2009). Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol 183: 2079-2088.
100. Raber J, O'Shea RD, Bloom FE, Campbell IL, (1997). Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci 17: 9473-9480.
101. Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF, (2015). From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 89: 541-554.
102. Ravenscroft JC, Suri M, Rice GI, Szynkiewicz M, Crow YJ, (2011). Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus. Am J Med Genet A 155A: 235-237.
103. Rehwinkel J, Maelfait J, Bridgeman A, Rigby R, Hayward B, Liberatore RA, et al. (2013). SAMHD1-dependent retroviral control and escape in mice. EMBO J 32: 2454-2462.
104. Rho MB, Wesselingh S, Glass JD, McArthur JC, Choi S, Griffin J, et al. (1995). A potential role for interferon-a in the pathogenesis of HIV-associated dementia. Brain Behav Immun 9: 366-377.
105. Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, et al. (2007). Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 81: 713-725.
106. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, et al. (2009). Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 41: 829-832.
107. Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, et al. (2012). Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet 44: 1243-1248.
108. Rice GI, Del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G, et al. (2014). Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 46: 503-509.
109. Rigby RE, Leitch A, Jackson AP, (2008). Nucleic acid-mediated inflammatory diseases. Bioessays 30: 833-842.
110. Rincon M, (2012). Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 33: 571-577.
111. Ronnblom LE, Alm GV, Oberg KE, (1990). Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227: 207-210.
112. Rose-John S, Heinrich PC, (1994). Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300 (Pt 2): 281-290.
113. Rose-John S, Scheller J, Elson G, Jones SA, (2006). Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80: 227-236.
114. Rossi JF, Lu ZY, Jourdan M, Klein B, (2015). Interleukin-6 as a therapeutic target. Clin Cancer Res 21: 1248-1257.
115. Rothwell NJ, Hopkins SJ, (1995). Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18: 130-136.
116. Ryan LA, Cotter RL, Zink WE 2nd, Gendelman HE, Zheng J, (2002). Macrophages, chemokines and neuronal injury in HIV-1-associated dementia. Cell Mol Biol 48: 137-150.
117. Rydberg B, Game J, (2002). Excision of misincorporated ribonucleotides in DNA by RNase H (type 2) and FEN-1 in cell-free extracts. Proc Natl Acad Sci U S A 99: 16654-16659.
118. Salsano E, Rizzo A, Bedini G, Bernard L, Dall'olio V, Volorio S, et al. (2013). An autoinflammatory neurological disease due to interleukin 6 hypersecretion. J Neuroinflammation 10: 29.
119. Samland H, Huitron-Resendiz S, Masliah E, Criado J, Henriksen SJ, Campbell IL, (2003). Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res 73: 176-187.
120. Sanz E, Hofer MJ, Unzeta M, Campbell IL, (2007). Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain. Glia 56: 190-199.
121. Scheller J, Garbers C, Rose-John S, (2014). Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 26: 2-12.
122. Seo YJ, Hahm B, (2010). Type I interferon modulates the battle of host immune system against viruses. Adv Appl Microbiol 73: 83-101.
123. Shet A, (2011). Congenital and perinatal infections: throwing new light with an old TORCH. Indian J Pediatr 78: 88-95.
124. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T, (1992). Interferon-a in lupus psychosis. Arthritis Rheum 35: 417-422.
125. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, et al. (2005). Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76: 528-537.
126. Spooren A, Kolmus K, Laureys G, Clinckers R, De Keyser J, Haegeman G, et al. (2011). Interleukin-6, a mental cytokine. Brain Res Rev 67: 157-183.
127. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD, (1998). How cells respond to interferons. Ann Rev Biochem 67: 227-264.
128. Steffensen SC, Campbell IL, Henriksen SJ, (1994). Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice. Brain Res 652: 149-153.
129. Steinman L, (2008). Nuanced roles of cytokines in three major human brain disorders. J Clin Invest 118: 3557-3563.
130. Stephenson JB, (2008). Aicardi-Goutieres syndrome (AGS). Eur J Paediatr Neurol 12: 355-358.
131. Stetson DB, Ko JS, Heidmann T, Medzhitov R, (2008). Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134: 587-598.
132. Taccone A, Gambaro G, Ghiorzi M, Ferrea G, Gianbartolomei G, Rolando S, et al. (1988). Computed tomography (CT) in children with herpes simplex encephalitis. Pediatr Radiol 19: 9-12.
133. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y, (2010). Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75: 208-216.
134. Tanaka T, Kishimoto T, (2012). Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 8: 1227-1236.
135. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. (2011). Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146: 621-632.
136. Tyor WR, Glass JD, Griffin JW, Becker PS, McArthur JC, Bezman L, et al. (1992). Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol 31: 349-360.
137. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. (2010). Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 16: 1443-1452.
138. Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, et al. (2013). Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 421: 181-183.
139. Uzawa A, Masahiro M, Kuwabara S, (2014a). Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol 24: 67-73.
140. Uzawa A, Mori M, Kuwabara S, (2014b). Neuromyelitis optica: concept, immunology and treatment. J Clin Neurosci 21: 12-21.
141. Valcour V, Sithinamsuwan P, Letendre S, Ances B, (2011). Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 8: 54-61.
142. Vallieres L, Campbell IL, Gage FH, Sawchenko PE, (2002). Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci 22: 486-492.
143. Van Wagoner NJ, Oh JW, Repovic P, Benveniste EN, (1999). Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci 19: 5236-5244.
144. Wang Q, Miyakoda M, Yang W, Khillan J, Stachura DL, Weiss MJ, et al. (2004). Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 279: 4952-4961.
145. de Weerd NA, Nguyen T, (2012). The interferons and their receptors-distribution and regulation. Immunol Cell Biol 90: 483-491.
146. Wu D, Lamm AT, Fire AZ, (2011). Competition between ADAR and RNAi pathways for an extensive class of RNA targets. Nat Struct Mol Biol 18: 1094-1101.
147. Xu WD, Zhang YJ, Xu K, Zhai Y, Li BZ, Pan HF, et al. (2012). IRF7, a functional factor associates with systemic lupus erythematosus. Cytokine 58: 317-320.
148. Yang W, Wang Q, Howell KL, Lee JT, Cho DS, Murray JM, et al. (2005). ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells. J Biol Chem 280: 3946-3953.
149. Yang YG, Lindahl T, Barnes DE, (2007). Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131: 873-886.
150. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C, et al. (2014a). Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature 517: 89-93.
151. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, et al. (2014b). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34: 11929-11947.
152. Zheng J, Thylin MR, Persidsky Y, Williams CE, Cotter RL, Zink W, et al. (2001). HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. Neurotox Res 3: 461-484.